HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


“Unprecedented” OCC funding

This article was originally published in The Rose Sheet

Executive Summary

House Appropriations Committee has approved a $2 mil. funding increase for FDA's Office of Cosmetics and Colors, which would strengthen the office's oversight of personal-care products and facilitate the development of global safety standards, according to CTFA. "Our strong partnership with FDA has been put at risk because [OCC] has shrunk to an inefficient level," CTFA President Pam Bailey notes in a release applauding the "unprecedented" funding. At CTFA's annual meeting in March, Bailey questioned the ability of OCC's staff - which she said has shrunk from 87 to 10 full-time employees since 1974 - to effectively oversee the $62 bil. personal-care market (1"The Rose Sheet" March 12, 2007, p. 3). "This [funding] increase will enhance consumer protections and provide [OCC] with much-needed inspectors and compliance officers," Bailey says...

You may also be interested in...

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts